66P Therapeutic opportunities in sarcomas and rare tumors: What path for antibody-drug conjugates?

H. Vanacker; M. Brahmi; P. Cassier; D. Pissaloux; S. Boyault; F. Tirode; Jean Yves Blay; A. Dufresne

doi:10.1016/j.esmoop.2023.101103

Back

66P Therapeutic opportunities in sarcomas and rare tumors: What path for antibody-drug conjugates?

Article 2023 en

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2025

Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates

Oliver Kepp, Guido Guido Kroemer

Article2025

Expression of antibody–drug conjugate targets in soft tissue sarcomas

François Bertucci, Pascal Finetti, Lénaïg Mescam, Audrey Monneur, A Frejafon, Axel Le Cesne, Isabelle Treilleux, Antoîne Italiano, M. Brahmi, Jean Yves Blay, Émilie Mamessier

Article2024

Abstract LB025: CKD-703, a novel antibody-drug conjugate targeting cMET with an enhanced therapeutic index in solid tumors

Kwan Woo Lee, S. Kim, Hye-Jin Hong, Eunjeong Park, Jungok Park, Seongho Hong, Daekwon Bae, Nina Ha, Sohn-Ji Yeon, Inchang Hwang, Se‐Mi Kim, Yoonseok Lee, Ju‐Hee Lee

Article2024

Precision Oncology in Soft Tissue Sarcomas and Gastrointestinal Stromal Tumors

Adam M. Fontebasso, Jeffrey D. Rytlewski, Jean Yves Blay, Rebecca A. Gladdy, Breelyn A. Wilky

Article2015

Engineering Biomaterial–Drug Conjugates for Local and Sustained Chemotherapeutic Delivery

Jeannine M. Coburn, David Kaplan